Introduction {#s1}
============

Exposure of arterial endothelium to low and disturbed flow initiates a process of endothelial activation, resulting in increased expression of adhesion molecules and the rolling, adhesion and extravasation of leukocytes ([@bib22]; [@bib38]). The level of shear stress to which endothelium is exposed is one of the best predictors of atherosclerosis and growth and rupture of aneurysms ([@bib4]; [@bib8]; [@bib10]; [@bib68]). Experiments with isolated endothelial cells exposed to altered flow in vitro revealed that increased laminar flow alone was sufficient to suppress endothelial apoptosis and expression of endothelial leukocyte recruitment molecules such as Icam1 ([@bib46]). Subsequent work revealed transcriptional programs induced by steady flow and suppressed by low and disturbed flow in vitro and in vivo ([@bib13]). Many of these programs could be recapitulated by Erk5 activation and increased expression of the transcription factor Klf2 ([@bib16]; [@bib41]; [@bib52]). Interfering with these programs increased markers of endothelial dysfunction and disease progression in atherosclerosis ([@bib16]; [@bib41]; [@bib52]). Thus, exposure of arterial endothelium to low flow initiates a program of endothelial dysfunction characterized by transcriptional changes and alterations in the expression of leukocyte recruitment molecules.

Most work to date has focused on the primary endothelial response to low flow, rather than the chronic interactions with immune cells under low flow in vivo. However, chronic inflammation contributes to a wide variety of dangerous cardiovascular lesions, including the erosion and rupture of atherosclerotic plaques and aneurysms. Not surprisingly, inflammation is a clinical target in atherosclerosis ([@bib55]) and aortic aneurysm ([@bib15]). The adaptive immune response is also being targeted, with good efficacy in pre-clinical models of atherosclerosis ([@bib34]). Historical perspectives on inflammation have typically focused on the leukocytes recruited in large numbers from the blood to the tissues, however, the endothelial lining of arterial vessels plays a critical role as a regulator of multiple steps in the cascade, including effects on immune cell recruitment, trafficking into tissues, and local activity ([@bib6]; [@bib19]; [@bib53]). The endothelium, as the interface between recruited immune cells and tissues, and as a local regulator of the inflammatory process, is an attractive target for the regulation of local inflammation, potentially avoiding complications of systemic immunosuppressive agents.

Recently, we discovered that, in a chronic in vivo model of low flow, changes in alternative splicing of the extracellular matrix protein fibronectin (FN) prevented hemorrhagic rupture of the intima ([@bib44]). Through alternative splicing, a single pre-mRNA produced from a transcribed gene can be spliced in different ways to generate multiple, sometimes hundreds, of various isoforms ([@bib48]; [@bib63]). These new isoforms often lend completely novel interactions to proteins, resulting in interaction profiles often as divergent from the 'canonical' isoform as from other unrelated proteins ([@bib69]). Interestingly, the splicing changes we observed in *Fn*, resulting in the incorporation of alternative exons *EIIIA* and *EIIIB*, could be blocked by the depletion of macrophages, which are recruited to the arterial endothelium under low flow ([@bib44]). Our results suggested that regulation of alternative splicing might play an important role in the endothelial interaction with recruited immune cells and regulation of chronic arterial inflammation.

Here, we test the possibility that alternative splicing is broadly regulated in the arterial endothelium by low and disturbed flow, and hypothesize that alternative splicing events co-regulated with alternatively spliced *Fn* exons *EIIIA* and *EIIIB* may be important in coordinating the response of the arterial endothelium to low flow.

Results {#s2}
=======

Low flow induces a program of alternative splicing in the arterial intima {#s2-1}
-------------------------------------------------------------------------

To determine the extent of alternative splicing changes in the arterial intima under low-flow conditions, we prepared pools of intimal RNA from the carotid arteries of mice exposed to low flow for 48 hr ([Figure 1A](#fig1){ref-type="fig"}). Control pools of RNA were prepared from mice subjected to a sham operation, or from the contralateral arteries of ligated mice, which were exposed to high flow. We detected 4766 differentially expressed genes between the low-flow carotid and the contralateral high-flow carotid (Padj \<0.05 by DEseq2, N = 3 per group), which overlapped and extended previous experiments in this system and in vitro ([@bib13]; [@bib47]) ([Figure 1B](#fig1){ref-type="fig"}). We observed excellent correlation in Log2 fold-change between biological replicates (Pearson correlation of 0.82 for all genes, and 0.98 for genes found to be significantly regulated by low flow). Low flow, rather than high flow in the contralateral artery, was responsible for the majority of changes in mRNA levels, relative to the normal-flow, sham-operated controls ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The flow-responsive signature included reduction in expression of the canonical flow-responsive genes *Klf2* and *Klf4* and we also detected an increase in signal from innate immune cells (*CD45*, *F4/80*, *CD11b*, *Cxcr2*; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), suggesting that such cells are recruited as early as 48 hr after the change in flow. However, transcripts from recruited or other contaminating cells represented a small portion of the total signal. This was assessed by the amount of *eGFP* (endothelial) mRNA copies versus *tdTomato* (all other cells) in *Cdh5(PAC)Cre-ERT2; mT/mG* mice, in which *eGFP* or *tdTomato* are driven from the same constitutive actin promoter in a cell-specific manner ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). By this measure, contaminating transcripts represented \<1.5% of RNA analyzed.

![Exposure of the arterial endothelium to low and disturbed flow induces a program of alternative splicing.\
RNA from the arterial endothelium was isolated 48 hr after partial carotid ligation; from the low-flow side, the high-flow side, or sham-operated vessels. (**A**) Outline of splicing analysis. Three pools of mRNA from each condition were isolated by polyA and sequenced. (**B**) Plot showing the consistency of changes in gene expression in two independent biological comparisons of low-flow versus high-flow isolations. (**C**) Number of RNA splicing events of each category detected by MISO analysis as significantly different in two independent biological comparisons. Events were drawn from annotated databases (Burge, Tian) or from custom annotation of mapped splice junctions (novel). (**D**) Plot showing the changes in skipped-exon inclusion level (deltaPsi) between low-flow and high-flow isolations. The plot also indicates changes in transcription, highlighting exons in genes with a change in FPKM of more than 2-fold up or down. (**E**) Processes enriched in the genes with regulated skipped exons, relative to the entire set of genes expressed in the tissue with annotated skipped exons which were not significantly regulated. Padj = Adjusted P-value, BF = Bayes Factor; FPKM = Fragments Per Kilobase of transcript per Million mapped reads; CCDS = Consensus Coding DNA Sequence.\
10.7554/eLife.29494.008Figure 1---source data 1.Contains DESeq2 output from the analysis of biological triplicates of low flow and biological triplicates of high flow, where each biological triplicate contained 4--5 carotid flushes.DESeq2 was performed on samples following STAR alignment and sequencing counts as described in methods.\
10.7554/eLife.29494.009Figure 1---source data 2.Contains MISO from Tophat alignments of 80 bp reads, as described in the methods.See GEO file GSE101826 for annotation of samples.\
10.7554/eLife.29494.010Figure 1---source data 3.Contains bowtie alignments to eGFP or tdTomato for the indicated samples as described in the methods.](elife-29494-fig1){#fig1}

Having established endothelial enriched RNA pools from the various flow conditions, we then asked whether alternative splicing in intimal endothelial cells was regulated by flow. We assessed levels of alternative exon inclusion, expressed as 'percentage spliced in' (Psi), in each condition and their differences using the MISO Bayesian statistical framework ([@bib33]). We examined annotated events as well as novel events (see Materials and methods). Setting a threshold of significance at Bayes factor five in two biologically independent comparisons of low flow to high flow, we identified 768 regulated splicing events between known exons (skipped or mutually exclusive exons, retained introns, or alternative 5' or 3' splice sites) and over a thousand regulated changes to the last exon or 3'UTR ([Figure 1C](#fig1){ref-type="fig"}). As with the transcript level changes, the vast majority of the splicing changes were induced by low flow, rather than high flow, in comparison with sham-operated vessels ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Approximately, 90% of the splicing changes observed in vivo were recapitulated (at least 50% in the same direction) in purified endothelial cells in vitro, supporting the endothelial regulation of these splicing events ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). It is not clear whether the 10% of events not similarly regulated in vitro reflect differences in the in vitro system or transcript variants from the \~1.5% contaminating mRNA.

Because the mechanisms of regulation of skipped exons are best understood, and because we are interested in alternative splicing events similar to the skipped exons in *Fn*, we focused on this subclass of alternative splicing events ([@bib44]). Changes in skipped exons were consistent between completely independent biological sets, and not obviously correlated with increased or decreased abundance in the transcriptional levels of these genes between conditions ([Figure 1D](#fig1){ref-type="fig"}, each point indicates a regulated splicing event, colored points indicate events in genes with altered transcript levels). The majority of the skipped exons were as strongly conserved evolutionarily as constitutive exons in placental mammals, and much more so than introns (data not shown). Genes with regulated skipped exons had annotated functions in several categories ([Figure 1E](#fig1){ref-type="fig"}). Thus, altered flow results in changes in RNA splicing of exons coincident with, but independent of, transcriptional changes.

Platelets are required for regulation of a subset of flow-regulated skipped exons {#s2-2}
---------------------------------------------------------------------------------

We previously observed that monocyte recruitment was required for increased inclusion of *Fn-EIIIA* and *EIIIB* exons after 48 hr of low flow ([@bib44]). Platelets and granulocytes are also recruited to arterial endothelium in regions of low and disturbed flow ([@bib9]; [@bib30]; [@bib42]). We depleted each of these recruited cell types using clodronate liposomes for macrophages ([@bib44]), anti-GPIbα for platelets and anti-Gr1 for neutrophils ([@bib36]). Platelets were essential for the recruitment of both macrophages and neutrophils in our system ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Platelet depletion resulted in suppression of *Fn-EIIIA* and *--EIIIB* relative to control treatments, and in widespread changes in a large number of other flow-regulated skipped exons ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). For the platelet-regulated skipped exons (about 1/3 of all flow-regulated skipped exons), platelet depletion causes low-flow arteries to cluster with high-flow arteries in their splicing profile rather than with IgG or untreated low-flow arteries ([Figure 2A](#fig2){ref-type="fig"}). Thus, platelets are necessary for the regulation of many of the low-flow regulated skipped exons we observed.

![Platelets and macrophages regulate a subset of flow-regulated skipped-exon events.\
(**A**) Effects of platelet depletion on splicing patterns in vivo (see also 2--2). Clustered heat map showing the change in skipped-exon inclusion frequency relative to high-flow contralateral arteries in biological replicates of untreated arteries (from data set created in [Figure 1](#fig1){ref-type="fig"}) or platelet-depleted (anti-GPIbα) or IgG control-treated (IgG) arteries. The data shown are for the platelet-dependent subset of all flow-regulated skipped exons (SE; 80/292). IgG and anti-GPIbα (low flow) are relative to average IgG (high flow). No antibody treatment in vitro and in vivo low flow are relative to average in vivo high flow. (**B**) Effects of platelet, macrophage and plasma addition to endothelial cells in vitro. (**B1**) Bar graphs showing in vitro changes in EIIIA inclusion frequency and Cd68 macrophage marker expression with the different treatments of conditionally immortalized aortic endothelial cells, relative to in vivo low-flow and high-flow samples. (**B2**) Plot showing the in vitro regulation of platelet-regulated skipped-exon events (40/80), in isolated and conditionally immortalized aortic endothelial cells. (**B3**) Clustered heat map, showing the change in skipped exon inclusion frequency in in vivo biological replicates of low-flow arteries with or without platelet depletion (in vivo low-flow+ IgG control, +GPIba) or conditionally immortalized aortic endothelial cells with the addition of the indicated cells or 10% plasma.\
10.7554/eLife.29494.015Figure 2---source data 1.Contains MISO from STAR alignments of 100 bp reads, as described in the methods.See GEO file GSE101826 for annotation of samples.\
10.7554/eLife.29494.016Figure 2---source data 2.Contains ratio of *EIIIA* or *EIIIB* to total *FN* in the indicated samples.](elife-29494-fig2){#fig2}

In vivo experiments were unable to discriminate between the effects of platelets and macrophages on the splicing response of endothelium, since platelet depletion suppressed macrophage recruitment. To address more directly the specific requirement for each blood cell type, we prepared a murine aortic endothelial cell line for in vitro co-culture experiments ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). We first examined *EIIIA* inclusion levels ([Figure 2B1](#fig2){ref-type="fig"}). Cultured cells in static conditions had higher baseline levels of *EIIIA* than high-flow arteries in vivo (compare bars 2 and 3). Co-culture with monocyte-derived macrophages, at similar stoichiometric ratios with the endothelial cells to those observed in vivo in low-flow arteries, did not further increase EIIIA inclusion. However, both platelets and plasma independently induced increased EIIIA inclusion, and exerted combinatorial effects, resulting in inclusion levels approximately 6-fold higher than in vivo levels when all three were added \[*EIIIA* (from 15% to 80%) and *EIIIB* (from 11% to 60%)\]. A broader examination of splicing changes, by RNA-seq, revealed that half (40 of 80) of the splicing events regulated by platelets in vivo were similarly regulated by a combination of platelets, macrophages and plasma in vitro ([Figure 2B2](#fig2){ref-type="fig"}). For this set of events, the addition of plasma, macrophages and platelets to cultured endothelial cells induced a low-flow-like change in splicing but the individual components - platelets, macrophages or plasma proteins - were unable to entirely recapitulate the potent effects of their combination ([Figure 2B3](#fig2){ref-type="fig"}). Thus, platelets alone were insufficient to induce low-flow regulated skipped exons, despite static in vitro conditions, and required both macrophages and plasma for maximal effect.

Together our results suggest that recruitment of both platelets and macrophages to the arterial endothelium is required for the flow-responsive splicing pattern in a large set of genes, including the *Fn-EIIIA* and *EIIIB* exons.

Binding motif for the splicing factor Rbfox2 is enriched in regulated vascular splicing events {#s2-3}
----------------------------------------------------------------------------------------------

We were particularly interested in the set of skipped exons induced in the endothelium in a platelet and macrophage-dependent manner, along with *Fn-EIIIA* and *--EIIIB*, and asked whether there might be a common upstream regulatory factor. Although analysis of transcriptional levels did not reveal obvious candidate splicing factors ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), the identity of relevant splicing regulators can in some cases be deduced by looking for enrichment of their RNA-binding motifs adjacent to regulated exons, where they typically bind to exert their effects ([@bib56]).

To take an unbiased approach to the identification of regulatory splicing factors by flanking motifs, we developed an analysis pipeline using the ranking algorithm in GSEA and taking advantage of the recent development of a comprehensive database of RNA-protein binding preferences (CisBP-RNA) to provide the RNA-binding protein 'finger-prints' to be ranked ([@bib54]). We confirmed that this pipeline was able to correctly identify known regulatory splicing factors from raw RNA-seq data from single-cell in vitro systems or complex in vivo tissues ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

Having confirmed our pipeline, we then applied it to assess the regulation of skipped exons in the increasingly narrowly defined group regulated in vivo and in vitro by recruited platelets and macrophages ([Figure 3A and B](#fig3){ref-type="fig"}). Enrichment was judged relative to background sets created from known skipped exons expressed but not regulated in endothelial cells (see Materials and methods for details). The Rbfox family, of which Rbfox2 is known to regulate *EIIIB* ([@bib62]), stood out among this group, being enriched especially on the downstream side of exons with decreased inclusion and, to a lesser extent, on both the upstream and downstream side of exons with increased inclusion ([Figure 3C--E](#fig3){ref-type="fig"}).

![Enrichment of an Rbfox motif in the platelet/macrophage-regulated subset identified in vivo and in vitro.\
(**A**) Motif analysis pipeline, showing the number of potentially regulated skipped-exon events, and those passing each filter. (**B**) Events were separated into those with increased or decreased inclusion, and then the sequences of the upstream and downstream 200 bp flanking regions were isolated, resulting in four regions of analysis. 6-mer motifs in each region were assessed for enrichment relative to exons expressed in six matched background sets of skipped exons not regulated by flow. GSEA was used to identify splicing factor 'fingerprints' among these enriched motifs, using the motif-binding preference defined by the CisBP-RNA database (Ray et al.). (**C**) Example of enrichment of Rbfox binding motif in GSEA analysis of 85-unique RNA-binding protein signatures against flanking intron sequences of flow-regulated exons. Plot shows enrichment of Rbfox family motifs among the motifs most enriched above background in the downstream flanking region of exons regulated in vivo and in vitro (set iii). (**D**) Enrichment of the Rbfox2 motif in each of the sets of biologically defined regulated exons (i-iii) within the upstream and downstream flanking regions of exons with either increased or decreased inclusion. (**E**) Plot showing the average z-score enrichment of the top 5 Rbfox in vitro defined motifs in the flanking regions of the in vivo regulated exon set (80 SE) and the in vitro regulated subset (40 SE), relative to the six matched background sets (N = 6 per bar). (**F**) Transcript levels of Rbfox family of proteins in the carotid artery in vivo and in isolated aortic endothelial cells in vitro, with or without the deletion of *Rbfox2* by *Cdh5(PAC)-CreER* (EC-KO). FPKM = Fragments Per Kilobase of transcript per Million mapped reads. FDR; false-discovery rate; n.f.; not found. p\<0.0001 (\*\*\*\*), p\<0.01 (\*\*).\
10.7554/eLife.29494.021Figure 3---source data 1.Contains the pared down list of flow-regulated events and their annotations (e.g. platelet regulated).See GEO file GSE101826 for annotation of samples.\
10.7554/eLife.29494.022Figure 3---source data 2.Contains the list of intervals used for motif enrichment around the indicated regulated exons for the indicated sets (e.g. increased inclusion in flow regulated set).\
10.7554/eLife.29494.023Figure 3---source data 3.Contains a list of expressions across samples for all known RNA binding proteins.\
10.7554/eLife.29494.024Figure 3---source data 4.Contains the list of all motifs, their enrichment adjacent to regulated exons, their conservation score, and the z-score enrichment of the motif from the CisBP-RNA database.](elife-29494-fig3){#fig3}

Rbfox2 motifs in the flanking regions of the regulated events were conserved, consistent with the conservation of the exons themselves ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). The Rbfox family contains three members, Rbfox1-3, with conserved RNA-binding motifs. To determine which of these might be most important in regulation of the *EIIIA* and *EIIIB* cohort of events, we examined their expression in vivo, and in in vitro purified endothelial cells. We found that only *Rbfox2* was significantly expressed in arterial endothelial cells ([Figure 3F](#fig3){ref-type="fig"}).

Thus, bioinformatics analysis suggests *Rbfox2* as a particularly important regulator of the skipped exon changes induced by platelet and macrophage recruitment to the arterial endothelium under low flow conditions.

Endothelial-specific deletion of *Rbfox2* partially reverts flow-responsive skipping of vascular skipped exons induced by low flow in vivo {#s2-4}
------------------------------------------------------------------------------------------------------------------------------------------

To test whether *Rbfox2* is involved in the splicing response of the arterial endothelium to low flow, we genetically removed *Rbfox2* in mice using an endothelial-specific and inducible Cre (*Cdh5(PAC)-CreERT2*) in combination with floxed *Rbfox2* alleles ([@bib21]; [@bib59]). This strategy resulted in efficient deletion of *Rbfox2* without an increase in expression of the other Rbfox family members, 1 and 3 ([Figure 3F](#fig3){ref-type="fig"}; EC-KO).

To allow us to assess both the low-flow-responsive splicing patterns and the chronic transcriptional response of the flow-activated intima, we examined the effect of *Rbfox2* deletion 7 days after the reduction in flow. Consistent with our previous observations on *Fn-EIIIA* and *--EIIIB*, we found that most splicing changes observed at 48 hr were also observed at 7 days ([@bib44]). We found that *Rbfox2* was important in the flow-responsive splicing change of many of the previously defined skipped exons, including *Fn-EIIIB* and *--EIIIA* to a lesser extent ([Figure 4A](#fig4){ref-type="fig"}, and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). Altogether, *Rbfox2* deletion suppressed flow-induced splicing changes of \~25% the skipped exons ([Figure 4A](#fig4){ref-type="fig"}, blue bars, right hand panel and 4B). This set of genes encodes extracellular matrix proteins (e.g. *Fn1*, *Fbln2*, *Mfge8*) and immune-regulatory proteins (e.g. *Ikbkg*, *Gpr116*, *Ceacam1*). Analysis of inclusion of specific exons is shown in [Figure 4C](#fig4){ref-type="fig"} demonstrating the loss of flow-responsive exons of *Fbln2* on endothelial deletion of *Rbfox2*.

![Endothelial Rbfox2 deletion affects many of the flow-regulated splicing events.\
(**A**) Showing the percentage of each group of skipped exons regulated by endothelial deletion of Rbfox2 (BF \>5) in any comparison and regulated similarly in both comparisons of Rbfox2 wt low-flow vs. Rbfox2 EC-KO low-flow -- either consistent with the flow-induced change in splicing (red, 'same') or against the direction of the flow-induced change in splicing (blue, 'reverted'). (**B**) Heat map showing the clustering of flow-regulated splicing events reverted by Rbfox2 deletion (67 of the 273 events consistently regulated between 48 hr and 7 days). 1 = C57 wild-type mice, 48 hr data set; 2 = C57 wild-type mice, IgG control 48 hr data set; 3 = Rbfox2 wt control (i.e. no Cre), 7 days data set; Rb EC-KO = Rbfox2 EC-KO 7 days data set. (**C**) Effect of endothelial *Rbfox2* deletion on flow-mediated regulation of inclusion of *Fbln2* alternative exons. (**D**) Plot shows the change in splicing of skipped exons (SE) following *Rbfox2* deletion from carotid artery intima in vivo (under low flow) or in isolated primary aortic endothelial cells in vitro. SE from the *Rbfox2* regulated set of events, in genes expressed \>FPKM 1 in in vitro and in vivo sets. SE also regulated by a change in flow are highlighted.\
10.7554/eLife.29494.028Figure 4---source data 1.Contains paired list of flow-regulated skipped exon events.**Event (mm9):** Skipped exon-splicing event, MM9 annotation; **ENSID, RefseqID, GeneID,  Rbfox2_regulated:** Regulated if Rbfox2 deletion was significantly altered splicing BF \>5 in any of the in vivo or in vitro comparisons; **High Flow 1:** Psi, 48 hr intima replicate 1 from contralateral artery pool; **High Flow 2:** Psi, 48 hr intima replicate 2 from contralateral artery pool; **Low Flow 1:** Psi, 48 hr intima replicate 1 from ligated artery pool; **Low Flow 2:** Psi, 48 hr intima replicate 2 from ligated artery pool; **IgG High Flow 1:** Psi, 48 hr intima replicate 1 from contralateral artery pool, IgG treated; **IgG High Flow 2:** Psi, 48 hr intima replicate 2 from contralateral artery pool, IgG treated; **IgG Low Flow 1:** Psi, 48 hr intima replicate 1 from ligated artery pool, IgG treated; **IgG Low Flow 2:** Psi, 48 hr intima replicate 2 from ligated artery pool, IgG treated; **Rbfox2 wt High Flow 1:** Psi, 7 days intima replicate 1 from contralateral artery pool, Rbfox2 ff; **Rbfox2 wt High Flow 2:** Psi, 7 days intima replicate 2 from contralateral artery pool, Rbfox2 ff; **Rbfox2 wt Low Flow 1:** Psi, 7 days intima replicate 1 from ligated artery pool, Rbfox2 ff **Rbfox2 wt Low Flow 2:** Psi, 7 days intima replicate 2 from ligated artery pool, Rbfox2 ff; **Rbfox2 EC-KO High Flow 1:** Psi, 7 days intima replicate 1 from contralateral artery pool, Cdh5(PAC)-CreERT2; Rbfox2 ff; **Rbfox2 EC-KO High Flow 2:** Psi, 7 days intima replicate 2 from contralateral artery pool, Cdh5(PAC)-CreERT2; Rbfox2 ff; **Rbfox2 EC-KO Low Flow 1:** Psi, 7 days intima replicate 1 from ligated artery pool, Cdh5(PAC)-CreERT2; Rbfox2 ff; **Rbfox2 EC-KO Low Flow 2:** Psi, 7 days intima replicate 2 from ligated artery pool, Cdh5(PAC)-CreERT2; Rbfox2 ff; **Rbfox2 wt in vitro:** Psi, cultured and sorted aortic endothelial cells from Rbfox2 ff; **Rbfox2 EC-KO in vitro:** Psi, cultured and sorted aortic endothelial cells from Cdh5(PAC)-CreERT2; Rbfox2 ff; **Platelet_regulated_50percent:** If platelet depletion reverted the low flow induced change in splicing by \>50%; **In_vitro_factor_regulated:** If addition of platelets, monocytes and plasma induced splicing changes \> 50% of those induced in vivo by low flow ;**Rbfox2_effect:** Consistent regulation, either increased or decreased, by deletion of Rbfox2 under low flow conditions in vivo; **SE_data_set:** *Burge v2 dataset (<http://miso.readthedocs.io/en/fastmiso/annotation.html>) or de novo identified events (see methods)*.](elife-29494-fig4){#fig4}

Since suppression of flow-responsive splicing was also impaired by depletion of platelets and macrophages, we asked whether recruitment of these cells was affected. However, we observed similar levels of macrophage markers (*Cd68, F4/80*) in the low-flow intimal flushes in the presence and absence of endothelial *Rbfox2* ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), suggesting that recruitment of macrophages, and by extension the platelets that we had previously found to be required for macrophage recruitment, were not detectably affected by deletion of *Rbfox2*.

Consistent with a direct effect of *Rbfox2* depletion on endothelial cells, we found a good correlation between the changes in splicing observed in vivo upon *Rbfox2* deletion and those observed in vitro with *Rbfox2* deletion in primary isolated aortic endothelial cells ([Figure 4D](#fig4){ref-type="fig"}). Notably, changes in splicing in vitro, in response to serum, did not correspond with an obvious alteration in the localization or abundance of Rbfox2 in the nucleus at the protein level ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

Thus, *Rbfox2* deletion in the endothelium prior to the induction of low flow suppresses a large portion of flow-responsive alternative splicing in endothelial cells, downstream of platelet and macrophage recruitment.

Endothelial deletion of *Rbfox2* alters the intimal response to low flow {#s2-5}
------------------------------------------------------------------------

We predicted that changes in the splicing response of the arterial intima caused by *Rbfox2* deletion would affect the response to low flow. To test this, we examined gene expression at the whole transcript level 7 days after the induction of low flow in *Rbfox2* EC-KO mice and littermate controls, and in the isolated endothelial cells. We found that endothelial deletion of *Rbfox2* significantly affected 641 genes in the carotid intima under low flow (DESeq2 p-adj \<0.05) ([Figure 5A](#fig5){ref-type="fig"}). Of these 641 genes, 507 are part of the 4766 gene low-flow signature previously described ([Figure 1](#fig1){ref-type="fig"}). Clustering of expression changes in the *Rbfox2*-regulated subset of genes, relative to the contralateral artery of control mice, shows that deletion of *Rbfox2* causes the low-flow arterial intima to resemble more closely the high-flow arterial intima ([Figure 5A](#fig5){ref-type="fig"}). Processes of cell proliferation and of antigen presentation were enriched among the differentially regulated genes ([Figure 5B](#fig5){ref-type="fig"}). RNA-seq was performed on pooled arteries, and quantitative PCR analysis of selected regulated genes in individual carotid arteries confirmed expression changes in individual animals ([Figure 5C and D](#fig5){ref-type="fig"}). These results indicate that Rbfox2 is essential for a portion of the endothelial response to low flow, regulating \~10% of the transcriptional response to low flow.

![Endothelial Rbfox2 deletion suppresses low-flow transcript response in the arterial intima.\
(**A**) Clustered heat map of the genes with adjusted p-values\<0.05 shows the change in expression relative to contralateral controls at 7 days after the change in flow in the indicated genotypes (N = 641). (**B**) Enriched terms among the genes regulated by Rbfox2 deletion. (**C**) Volcano plot showing DESeq2 calculated p-values and log2 fold changes in genes expressed in the arterial intima at 7 days of arteries exposed to low and disturbed flow, with or without deletion of *Rbfox2*. Genes selected for qPCR in single arteries are shown. (**D**) Results of individual carotid artery qPCR for the genes indicated. Log2 fold-changes are relative to control, p values are from Mann-Whitney test (N = 14 control and N = 18 Rbfox2 EC-KO).\
10.7554/eLife.29494.031Figure 5---source data 1.Contains qPCR deltaCT between gene and housekeeping gene in the indicated samples, and the normalization to controls used to determine fold-change.](elife-29494-fig5){#fig5}

In contrast with our observation of correlations between splicing patterns in vivo and in vitro, most transcriptional changes induced in the low-flow arterial intima were specific to the in vivo environment and were not observed in a comparison of isolated aortic endothelial cells or in the contralateral artery ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In other systems, cytoplasmic Rbfox has been shown to have an important role in the regulation of transcript stability through the 3'UTR ([@bib14]; [@bib37]). However, transcript levels regulated by *Rbfox2* were not any more associated with characterized 3' UTR binding by iClip-Seq ([@bib37]) than those not regulated by *Rbfox2* (iClip-Seq binding sites in 54/638 of the *Rbfox2*-regulated transcripts versus 1166/17130 of the transcripts not regulated by *Rbfox2*). Together, these data suggest that the consequences of endothelial Rbfox2 deletion on transcriptional changes involved cross-talk among cell types (e.g. effects of altered endothelial splicing on recruited immune cells) or other microenvironmental effects in the flow-activated intima in vivo not replicated in vitro.

Thus, *Rbfox2* deletion affects skipped exon splicing patterns in endothelial cells, and results in the reversion of a large set of low-flow-induced gene expression changes in the arterial intima.

Discussion {#s3}
==========

Here, we report that recruitment of circulating hematopoietic cells to the arterial endothelium under low flow initiates an alternative splicing response regulated in part by *Rbfox2*. Profiling global transcriptional changes induced in the arterial endothelium by experimentally induced low flow, we show that hundreds of transcripts are regulated by alternative splicing. Focusing on skipped exons in particular, we find that one third of those affected by altered flow are dependent on recruited hematopoietic cells in vivo, particularly platelets. Rbfox-binding motifs are significantly enriched adjacent to these exons. Mechanistically, deletion of endothelial *Rbfox2* reverts many of the flow-induced changes in splicing and suppresses \~10% of the flow-induced changes in transcription. Processes related to genes with changes in either splicing or transcription included cytoskeleton, cell adhesion, proliferation and antigen presentation suggesting that *Rbfox2* may regulate these biological processes in the aortic intima downstream of hematopoietic cell recruitment.

Broad regulation of alternative splicing by flow in the arterial endothelium {#s3-1}
----------------------------------------------------------------------------

Low flow exerts potent effects on the vasculature through the endothelium, which are achieved by effects on endothelial transcription, epigenetic regulation, and post-translational protein modifications and reorganization ([@bib23]). Our work reveals widespread changes in alternative splicing affecting a number of genes known to be critical in the pathways already implicated in the response to altered flow, inflammation, remodeling and flow-driven vascular disease. Examples include *Pecam1*, a component of the shear-sensing mechanism in the endothelium ([@bib61]), *Yap1*, a regulator of mechanical activation ([@bib18]) and *Ikbkg (Nemo),* a regulator of NFkappa-B signaling ([@bib39]). In previous work, differential splicing of *Vcam1* was detected in IL-1-stimulated HUVECs ([@bib12]) and of *Fn* in TGFβ-induced liver sinusoidal endothelium ([@bib7]). Exon arrays have also shown differential exon usage in HUVECs in response to hypoxia ([@bib25]; [@bib67]). However, this hypoxic response appears to be very different from the responses we have observed, and less then 2% of the genes in which we detected alternative splicing overlap with those found in the hypoxic signature of HUVECs. It is possible that this is due to methods used (exon arrays versus our sequencing approach), cell type (HUVECs versus murine aortic endothelial cells), or pathway-specific responses. The latter is likely, since we observed no consistent regulation of hypoxia-induced genes (e.g. *Vegfa*) in the flow-responsive signature. Alternative splicing responses are distinct, similar to transcriptional responses ([@bib24]). Indeed, even within the alternative-splicing response to altered flow, we are able to detect a distinct response dependent on the recruitment of circulating hematopoietic cells.

Biological consequences of alternative splicing programs induced by low flow {#s3-2}
----------------------------------------------------------------------------

We do not yet know the function of most of the splicing changes we have observed. Unlike mice deficient in both *EIIIA* and *EIIIB*, which exhibit an increased risk of arterial rupture under low flow, *Rbfox2 EC-KO* mice do not. This may be due to the lesser effect of *Rbfox2* deletion on *EIIIA* than *EIIIB* in the *Rbfox2* mutant mice (*EIIIA* inclusion was 50% in *Rbfox2 EC-KO* low-flow artery, versus 60% in WT low-flow artery, compared with 20% in high flow artery; while *EIIIB* inclusion was absent in all *Rbfox2 EC-KO* conditions). In previous work, we found that *EIIIA-/-* replicated much of the effect of the *EIIIAB-/-* mice; loss of *EIIIB* may have other consequences than loss of *EIIIA* ([@bib44]).

Nevertheless, we have reason to believe that these splicing changes are biologically important. First, the alternatively spliced exons comprising this response, including *Fn-EIIIA* and *-EIIIB*, are highly conserved among all placental mammals. In fact \~80% of the flow-regulated skipped exons are as well conserved as consensus coding exons (CCDS). Conservation of sequence is not necessarily the same as conservation of regulation ([@bib32]; [@bib40]; [@bib43]; [@bib51]; [@bib70]). Nevertheless, the conservation of regulatory regions, specifically the Rbfox2 motif, surrounding the skipped exons support conserved regulation as well. Second, deletion of a regulator of this splicing program, *Rbfox2*, affects the transcriptional response of the intima to low flow. Notably, both genes with *Rbfox2*-regulated transcript levels, and those with *Rbfox2*-regulated skipped exons were enriched in functions related to cytoskeletal remodeling, cell adhesion, and antigen presentation ([Figure 1](#fig1){ref-type="fig"} and [Figure 5](#fig5){ref-type="fig"}). The particular genes regulated in each way (transcript abundance and splicing) did not directly overlap, suggesting that similar biological processes may be targeted through both transcriptional and post-transcriptional mechanisms in *Rbfox2 EC-KO* mice. Given the known activation of TLR4 signaling by EIIIA ([@bib50]), a key player in adaptive immunity, the potential impact on antigen presentation and the adaptive response warrants further research.

Regulation of alternative splicing in the aortic endothelium by platelets and macrophages {#s3-3}
-----------------------------------------------------------------------------------------

Much of the work to date on flow-induced changes in gene expression in the arterial endothelium has focused on the initial response to flow, which increases the transcriptional expression of adhesion receptors and chemokines involved in the recruitment of circulating immune cells ([@bib11]; [@bib38]). This has been a consequence of efforts to identify the first events leading to endothelial dysfunction under low flow. However, once circulating hematopoietic cells are recruited, they initiate ongoing interactions in the arterial wall likely to affect the ultimate outcome of flow-induced arterial injury ([@bib53]). Flow-driven vascular inflammation occurs as a chronic process, involving components of the innate and adaptive immune systems ([@bib19]; [@bib53]). Here, we show that recruitment of platelets and monocytes/macrophages in particular potently regulate alternative splicing in the arterial endothelium. Within this response, we observed alterations in a number of pathways that may impact ongoing interactions at the arterial wall. Thus, subsequent to the well-studied events leading to recruitment of immune cells, their interactions with the arterial endothelium appear to be affecting pathways that may help to shape the chronic inflammatory response.

Endothelial functions of Rbfox2 {#s3-4}
-------------------------------

Rbfox2 is one of three Rbfox family members (Rbfox-1,-2 and -3). The Rbfox family of splice factors and the motif recognized by their RNA-binding domain are conserved throughout the vertebrates examined and also in *C. elegans* ([@bib62]). The motif which the Rbfox family recognizes was first identified adjacent to *Fn-EIIIB* ([@bib28], [@bib29]), which we find to be dependent on Rbfox2 in our system, consistent with previous work in other systems ([@bib31]). The Rbfox family has been shown to have important functions in heart ([@bib20]), muscle ([@bib57]), and brain development ([@bib21]) and EMT in cancer ([@bib56]). De novo mutations in *Rbfox2* have also been identified in congenital heart disease ([@bib26]), and alterations in Rbfox2 activity may be an early event in diabetes-induced heart pathology ([@bib49]). In both heart and brain, Rbfox2 has been shown to have a requirement in maintenance of tissue functions ([@bib20]; [@bib21]). In contrast to the other tissues mentioned, *Rbfox2* is the only member of the Rbfox family expressed in the arterial endothelium.

How *Rbfox2* modulates splicing activity in this system remains unknown. We observe modest changes in expression of Rbfox2 (\<20% increase in RNA in arterial endothelium exposed to low flow in vivo). Similar modest changes were observed in the in vitro system, in which we induced splicing changes with co-culture of platelets, monocytes and plasma. How else might Rbfox2 splicing activity be regulated? One possibility we examined is that upstream cues from platelet and monocyte recruitment alter sub-cellular localization of the Rbfox2 protein. However, we observed no obvious loss in nuclear Rbfox2 localization in vitro under conditions in which splicing changes are induced ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), suggesting that activity may be regulated in some other way. These data, together with the observation that deletion of *Rbfox2* results in splicing alterations more widespread than the low-flow response alone ([Figure 4D](#fig4){ref-type="fig"}), suggest that the specificity of the endothelial splicing response is driven by other flow-responsive factors acting in an *Rbfox2-*dependent manner.

We have focused on the splicing functions of *Rbfox2*. However, in addition to affecting splicing patterns, *Rbfox2* has also been reported to regulate gene expression patterns by other mechanisms. Splicing of Rbfox2 targets has been shown to regulate transcript stability ([@bib31]). Through recruitment of polycomb complexes to DNA, Rbfox2 may affect transcript expression ([@bib66]). Rbfox2 may also stabilize transcripts directly by binding to the 3'UTR ([@bib14]; [@bib37]), suppressing the formation of isoforms destined for nonsense-mediated decay ([@bib31]). However, as we observed no enrichment of known Rbfox-binding sites in the 3'UTR of regulated transcripts and no regulation of transcript levels in vitro which were regulated in vivo, we believe that many of the transcript level changes mediated by deletion of Rbfox2 are due to downstream or non-cell autonomous effects. Future work, examining the functional effects of individual splicing events identified will be important in teasing apart splicing-dependent and -independent effects.

In conclusion, we report that hundreds of splicing changes are regulated in endothelial cells exposed to an acute reduction in blood flow, many of which were dependent on recruitment of platelets and monocytes to the arterial wall and impact key pathways in endothelial cell biology. Rbfox2 emerged as an important regulator in this system, and its depletion resulted in a partial suppression of transcriptional responses characteristic of low-flow-induced endothelial activation. Thus, *Fn* is only one of many genes affected by splicing changes in the activated vascular endothelium. Alterations in *Fn* splicing contribute to a variety of vascular diseases with an inflammatory component; stroke ([@bib17]), atherosclerosis ([@bib60]), myocardial infarction ([@bib1]), organ transplant and other fibroses ([@bib2]; [@bib3]). Therefore, further investigation of the other alternative splicing events we have identified here may uncover novel regulatory mechanisms in chronic inflammatory disease.

Materials and methods {#s4}
=====================

  Reagent type (species) or resource          Designation                           Source or reference                           Identifiers
  ------------------------------------------- ------------------------------------- --------------------------------------------- ------------------------------------------------------------------------
  antibody                                    anti-GP1bα                            Emfret                                        RRID:[AB_2721041](https://scicrunch.org/resolver/AB_2721041)
  antibody                                    anti-Gr1                              Biolegend                                     RRID:[AB_467731](https://scicrunch.org/resolver/AB_467731)
  antibody                                    anti-Rbfox2                           Bethyl Labs                                   RRID:[AB_609476](https://scicrunch.org/resolver/AB_609476)
  commercial assay or kit                     SMARTer Universal Low Input RNA Kit   Clontech                                      
  commercial assay or kit                     RNAeasy microcolumns                  Qiagen                                        
  software, algorithm                         RSEM v.1.2.15                         GitHub                                        RRID:[SCR_013027](https://scicrunch.org/resolver/SCR_013027)
  software, algorithm                         MISO v.0.4.9                          GitHub                                        RRID:[SCR_003124](https://scicrunch.org/resolver/SCR_003124)
  software, algorithm                         STAR 2.5.1b                           GitHub                                        RRID:[SCR_015899](https://scicrunch.org/resolver/SCR_015899)
  software, algorithm                         Tophat 2.0.6                          GitHub                                        RRID:[SCR_013035](https://scicrunch.org/resolver/SCR_013035)
  software, algorithm                         Bowtie2 v. 2.0.5                      GitHub                                        RRID:[SCR_005476](https://scicrunch.org/resolver/SCR_005476)
  software, algorithm                         GSEA                                  <http://www.gsea-msigdb.org/gsea/index.jsp>   RRID:[SCR_003199](https://scicrunch.org/resolver/SCR_003199)
  strain, strain background (*M. musculus*)   *Rbfox2^lox/lox^*                     Jackson Lab                                   RRID:[IMSR_JAX:014090](https://scicrunch.org/resolver/IMSR_JAX:014090)
  strain, strain background (*M. musculus*)   *Rosa26-mTmG*                         Jackson Lab                                   RRID:[IMSR_JAX:007676](https://scicrunch.org/resolver/IMSR_JAX:007676)
  strain, strain background (*M. musculus*)   *Cdh5(PAC)-CreERT2*                   Jackson Lab                                   RRID:[IMSR_TAC:13073](https://scicrunch.org/resolver/IMSR_TAC:13073)
  strain, strain background (*M. musculus*)   C57BL/6J                              Jackson Lab                                   RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)

Flow alterations {#s4-1}
----------------

Partial carotid ligations were performed as previously described ([@bib47]), with minor modifications ([@bib44]). Briefly, the distal branches of the left carotid artery were identified in mice anesthetized with isoflurane. The left external carotid, internal carotid, and occipital artery were ligated with 9--0 Ethilon suture, leaving only the superior thyroid artery intact. Sham operations consisted of the same carotid dissection and encircling with suture, except that the vessels were not tied off. High-resolution ultrasound, using the VisualSonics Vevo 770, was performed at the experimental endpoint (2--7 days after partial carotid ligation) to confirm vessel patency.

RNA-isolation and sequencing {#s4-2}
----------------------------

Isolation of intimal RNA was performed as previously described from the carotid intima ([@bib44]; [@bib47]). Briefly, vessels were isolated and imaged from euthanized mice, flushed with PBS solution and then 150 µL Trizol. RNA from cultured aortic endothelial cells was isolated after one week in culture by sorting 1--2K endothelial cells (by CD31+ and Icam2+) from BD Aria directly into cold Trizol solution. RNA from all samples was isolated with Qiagen RNAeasy microcolumns. Pools of RNA were created and then DNAse-treated in solution, before concentrating on RNAeasy columns with elution in minimal volume. RNA quality was assessed by Agilent Bioanalyzer or Advanced Analytical, library preparation was performed using the Clontech SMARTer Universal Low Input RNA Kit, and samples were sequenced on Illumina HiSeq 2000 or NextSeq 500 using 80 bp paired-end (PE) reads (triplicates of low-flow, sham and high-flow), 100 bp PE reads (re-sequencing of triplicates of low-flow, sham and high-flow, and cultured aortic endothelial cells) or 150 bp PE reads (hematopoeitic cell depletions with controls and endothelial Rbfox2 deletion with controls in vivo and in vitro). Base calls were performed using the Offline Base Caller (Illumina) v. 1.9.4 and reads mapping to different genomic features were tallied and read densities were compared for each sample.

Read-mapping and transcript analysis {#s4-3}
------------------------------------

For experiments with alteration of flow (triplicates of low-flow, sham and high-flow), reads were trimmed to 80 bp and mapped with Tophat 2.0.6 and Bowtie2 v. 2.0.5, allowing the detection of novel junctions, with options -p 8 \--read-edit-dist 4 \--min-intron-length 10 \--read-mismatches 4 \--max-intron-length 1000000 \--read-realign-edit-dist 0 \--mate-std-dev 30 \--segment-length 20 \--library-type fr-firststrand -r 50, guided (-G) by an mm9-based refseq gtf file \[https://www.ncbi.nlm.nih.gov/pubmed/23618408\].

For experiments with alteration of flow with or without depletion of hematopoeitic cells or deletion of Rbfox2, 150 bp reads were mapped with STAR 2.5.1b and options \--runThreadN 8 \--runMode alignReads \--outFilterType BySJout \--outFilterMultimapNmax 20 \--alignSJoverhangMin 8 \--alignSJDBoverhangMin 1 \--outFilterMismatchNmax 999 \--alignIntronMin 10 \--alignIntronMax 1000000 \--alignMatesGapMax 1000000 \--outSAMtype BAM SortedByCoordinate \--quantMode TranscriptomeSAM \[https://www.ncbi.nlm.nih.gov/pubmed/23104886\].

RSEM v.1.2.15 (options \--paired-end \--calc-ci -bam -p 8 ) was used to calculate transcript levels \[<https://www.ncbi.nlm.nih.gov/pubmed/21816040>\], and DESeq2 v1.10.1 in the R statistical environment v3.2.3 was used to calculate differential transcript levels using the DEseq() integrated command with default parameters, which estimates library sizes and dispersions and fits a negative binomial generalized linear model for fold-changes and Wald statistics estimation using a 2-condition design. \[<https://www.ncbi.nlm.nih.gov/pubmed/25516281>\].

For *eGFP* and *Tomato* analysis, a custom index containing *eGFP* and *tdTomato* sequences was created, and bowtie was used to align reads to this index using options \--best \--strata -m 1 --q. The number of reads mapping to *eGFP* and to *tdTomato* were counted, and % tdTomato reads determined \[*tdTomato* reads / (*tdTomato+ eGFP* reads) \*100%\].

Splicing analysis {#s4-4}
-----------------

Positive control data sets for regulation of splicing by *Rbfox2 in vitro* or by *Mbnl in vivo* were taken from published data, and run through our own informatics pipeline ([@bib31]; [@bib65]).

MISO v.0.4.9 was used to determine differential splicing regulation. The SE, A3SS, A5SS, RI and MXE event index was derived from the MISO splicing events database (mm9 version 2). Briefly, this set of events was derived by considering all transcripts annotated in Ensembl genes, knownGenes (UCSC) and RefSeq genes (as of June 2013). The ALE and TandemUTR events index was derived from the MISO database compiled from published data, made available on the MISO website ([@bib27]). Additional novel SE, A3SS, A5SS and MXE events were detected using a method developed by Paul Boutz. Identification and classification of novel alternative splicing events was performed as described in [@bib5]. Briefly, mapped splice junctions were filtered for minimal transcript level and classified as SE, A3SS, A5SS, or MXE without reference to annotated exonic loci. This set of novel events was then used to generate a novel index, which was passed through the same MISO pipeline as all other indices.

Selection of subgroups of regulated exons {#s4-5}
-----------------------------------------

*Flow-regulated*: BF \>5 in two completely independent biological comparisons of low flow versus high flow, where the difference between high flow and low flow is \>2 x the difference between replicate high-flow conditions.

### Flow-regulated and endothelial {#s4-5-1}

Of the events above, at least 50% of the difference between low-flow in vivo and high flow in vivo must be recapitulated in differences between FACs-purified mouse arterial cells in culture and high-flow cells in vivo.

### Flow-regulated and endothelial and platelet-regulated {#s4-5-2}

Of the events above, if platelet depletion reverted flow-induced splicing changes by \>50% in two completely independent biological comparisons.

### Flow-regulated and endothelial and platelet-regulated and in vitro regulated {#s4-5-3}

Of the events above, if the change in splicing induced in isolated aortic endothelial cells by the addition of platelets, macrophages and plasma was \>50% of the flow-regulated change in splicing.

### Rbfox2-regulated {#s4-5-4}

If change in inclusion with Rbfox2 deletion was BF \>5 in any of three comparisons, in vivo low-flow Rbfox2 control vs. Rbfox2 EC-KO artery at 7 days, in vivo high-flow Rbfox2 control vs. Rbfox2 EC-KO artery at 7 days, or in vitro Rbfox2 control vs. Rbfox2-deleted aortic endothelial cells, and consistently changed in the same direction in all in vivo comparisons under low flow between Rbfox2 control and Rbfox2 EC-KO arteries. In this set, Rbfox2 control arteries have floxed alleles but no Cre activity.

Identification of enriched splice factor motifs adjacent to regulated skipped exons {#s4-6}
-----------------------------------------------------------------------------------

To perform motif enrichment analysis, we compared endothelial alternative skipped exons regulated by blood cells in vivo and in vitro (the foreground) with skipped exons expressed by endothelial cells, but not consistently regulated under the same conditions (the background). In general, the foreground events were more often poised at an intermediate Psi level (neither complete inclusion or exclusion). They also tended to be expressed at a higher level than background events. Thus, we created background sets in which we normalized each of these parameters independently (data not shown). We looked for motifs enriched either upstream (3'splice site, or 3'SS) or downstream (5' splice site, or 5'SS) of the regulated exons. Since the direction of change in exon inclusion, increased dPsi or decreased dPsi, has been correlated with the location of splice factor binding, we further separated the foreground into exons with increased (+dPsi) or decreased (-dPsi) inclusion. Intronic sequences adjacent to the 3'SS and the 5'SS of skipped exons with increased or decreased inclusion were isolated from mm9 sequence data using Bedtools 2.16.1 (getfasta --s), and enrichment was calculated based on enrichment of 6-mer or 7-mer motifs in the foreground versus the background sets, split across 10 GC-normalized bins, iterated multiple times.

From the lists of enriched motifs we obtained, we aimed to identify the likely RNA-binding proteins. To do this in an unbiased manner, we used the CisBP-RNA data set, which includes 154 unique motifs and 373 total murine RNA-binding proteins ([@bib54]). We modified the ranking algorithm GSEA, typically used to identify transcriptional signatures, to identify RNA-binding protein signatures. A Kolmogorov-Smirnov statistic embedded in GSEA was used to identify which of these RNA-binding-protein motif sets was most abundant at the leading edge of the ranked enrichment set ([@bib58]).

Depletion of innate immune cells {#s4-7}
--------------------------------

For platelet depletion experiments, mice were injected intraperitoneally with a single dose of platelet-depleting antibody (anti-GP1bα; 50 µg per mouse; R300; Emfret; RRID:[AB_2721041](https://scicrunch.org/resolver/AB_2721041)) or IgG control at the time of partial carotid ligation. To deplete Ly6G+ cells, anti-Gr1 (RB6-8C5; BioLegend; RRID:[AB_467731](https://scicrunch.org/resolver/AB_467731)) or IgG controls were administered by intraperitoneal injection (25 µg per mouse) 24 hr prior to partial carotid ligation. To deplete macrophages, mice were injected by tail vein with 150 µL clodronate liposomes or PBS liposome controls at the time of partial carotid ligation. Clodronate liposomes or PBS liposomes were purchased from ClodronateLiposomes.com (Kruisweg 59, 2011 LB Haarlem, The Netherlands).

Mice {#s4-8}
----

Male C57BL/6J mice from Jackson Laboratories were used at 6--7 weeks of age for experiments on the regulation of transcription and splicing in the carotid intima in wild-type mice, or in wild-type mice with the depletion of various hematopoietic cells.

For the endothelial deletion of Rbfox2, *Cdh5(PAC)-CreERT2, Rosa26-mTmG* and *Rbfox2^lox/lox^* mice have been previously described ([@bib21]; [@bib45]; [@bib64]) RRID:IMSR_JAX:014090, RRID:IMSR_JAX:007676, RRID:IMSR_TAC:13073. They were intercrossed to create the Rbfox2 EC-KO mice *(Cdh5(PAC)-CreERT2; Rosa26-mTmG; Rbfox2^lox/lox^)* and littermate controls (*Rosa26-mTmG* and *Rbfox2^lox/lox^*) used here. Mice used were between 2 and 7 months of age in paired groups of males and females.

All mice were housed and handled in accordance with protocols approved by the Massachusetts Institute of Technology Division of Comparative Medicine.

Aortic endothelial cell isolation {#s4-9}
---------------------------------

Mouse aortic endothelial cells were isolated following previously described methods ([@bib35]), with modifications. Briefly, mice were perfused via the left ventricle with PBS, the aorta was isolated and filled with 2% collagenase II (Worthington) in serum-free DMEM, and then closed at the ends with 7--0 suture. The vessel was digested for 30--45 min in 10% FBS at 37C, and endothelial cells were flushed out into EC culture medium, and onto a collagen I-coated plate. EC culture medium consisted of DMEM with 10% FBS and 10 mg/mL endothelial growth supplement (ECGS, Biomedical Technologies) with primocin (InvivoGen). Typical isolations of \~1000 cells expanded to \~10,000--50,000 cells. Cells were then FACs-sorted (BD Aria) on endothelial markers, eGFP for *Cdh5(PAC)-CreERT2; Rosa26-mTmG* on Pecam+ and Icam2+ for *Cdh5(PAC)-CreERT2; Rosa26-mTmG; Rbfox2^lox/lox^* mice and littermate controls.

Aortic endothelial cell immortalization {#s4-10}
---------------------------------------

After purification by FACs, endothelial cells were immortalized by lentiviral TetOn-Sv40T. The construct was developed from a version of pTRIPZ (Clontech) with removal of the puro-selection cassette. SV40 T antigen was inserted into the tet-regulated region of the lentivirus from pBabe-SV40T ([@bib71]). After infection, cells were expanded in EC media with 2 µg/mL Doxycycline (Dox).

Aortic endothelial cell co-culture {#s4-11}
----------------------------------

Cells derived from *Cdh5(PAC)-CreERT2; Rosa26-mTmG*, tamoxifen-treated in vivo, and then isolated by FACs purification on eGFP, expanded and immortalized by TetOn-SV40T were trypsinized and split in DMEM into new dishes, without Dox to turn off SV40T. After culture for 24 hr in DMEM, combinations of platelets, bone-marrow-derived monocytes, and/or 10% plasma were added for 48 hr. Cells in plate were then imaged and lysed with Trizol for RNA extraction.

Platelets were isolated from the platelet-rich plasma (PRP) of C57BL/6J mouse blood by collection in ACD buffer. They were spun down at 500xG for 7 min with isolation of the upper PRP, from which a platelet pellet was isolated after being spun down at 2800xG for 5 min and resuspended in PIPES buffer. \~20 million platelets (in 6 µL PIPES) were added to each confluent well of endothelial cells in the 24-well plate. Plasma was taken from C57BL/6J mouse blood collected in EDTA and spun down at 2000xG for 15 min at 4°C. 10% plasma was added to DMEM in 24-well plates. Bone-marrow-derived monocytes were isolated from the femurs of C57BL/6J mice, flushed with 10% FBS DMEM (+2 mM EDTA) into collection tube with 10 mL syringe and 25Ga needle, and then purified using an EasySep Mouse Monocyte Isolation Kit (by negative selection, depleting Cd3+, Cd45R+, Cd117+, Ly6G+, Nk1.1+, Siglec F+ cells). \~10K monocytes were added to each well of the 24-well plate.

Aortic endothelial cell immunofluorescence {#s4-12}
------------------------------------------

Cells (TetOn-Sv40, eGFP+ from *Cdh5(PAC)CreERT2; mT/mG* mice were cultured on poly-L-lysine treated coverslips and treated or not with 10% serum (FBS) for 48 hr. Coverslips and cells were washed with phosphate buffered saline (PBS) and fixed with ice cold methanol. Rbfox2 protein was stained by anti-Rbfox2 (Bethyl Labs A300-864A, 1:1000; RRID:[AB_609476](https://scicrunch.org/resolver/AB_609476)), with goat anti-rabbit Alexa594 secondary. Block was 10% normal goat serum in PBS with 0.1% tritonX-100.
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The following dataset was generated:

Murphy PAButty VLBoutz PLBegum SSharp PABurge CBHynes RO2017Alternative RNA Splicing in the Endothelium Mediated in Part by Rbfox2 Regulates the Arterial Response to Low Flow<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101826>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE101826)

The following previously published datasets were used:

Wang ETCody NAJog SBiancolella MWang TTTreacy DJLuo SSchroth GPHousman DEReddy SLécuyer EBurge CB2012Transcriptome-wide Regulation of Splicing and mRNA Localization by Muscleblind Proteins<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39911>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE39911)
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Thank you for submitting your article \"Alternative RNA Splicing in the Endothelium Mediated in Part by Rbfox2 Regulates the Arterial Response to Low Flow\" for consideration by *eLife*. Your article has been favorably evaluated by James Manley (Senior Editor) and two reviewers, one of whom, Douglas Black, is a member of our Board of Reviewing Editors..

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This paper from the Hynes group examines the role of alternative splicing in the response of arterial endothelium to low blood flow. Endothelial recruitment of inflammatory cells in response to low flow is important in a variety of vascular diseases including atherosclerosis. Earlier work identified endothelial gene expression changes induced by the recruitment of platelets and additional cell types to sites of low flow and also showed that changes in the splicing of fibronectin (Fn) were important. Here the authors do a broader analysis, using carotid ligation to model low flow in the mouse and applying RNAseq to identify changes in splicing pattern across the transcriptome. This identified a large number of altered transcripts. They develop similar results in cultured endothelial cells and use antibody depletion of platelets or macrophages to identify the set of splicing changes responsive to the recruitment of these cells, which include the aforementioned Fn. Examining the cassette exons among the platelet/macrophage responsive splicing events, they find enrichment for the binding site of Rbfox family splicing regulators in the introns adjacent to the flow regulated exons. They show that Rbfox2 is expressed in the endothelium and use a conditional Rbfox2 allele to conditionally knock it out of these cells with the Cdh5-Cre driver. Examining the splicing in the knockout mice, they find that a substantial subset of the low flow responsive exons require Rbfox2 in their regulation. Finally, they find that many of the previously characterized gene expression changes in low flow conditions also require Rbfox2. These data point to a new posttranscriptional genetic regulatory program mediating endothelial responses to blood flow.

The reviewers all found this paper to be novel and interesting. Alternative splicing and the program of Rbfox regulation specifically are likely to be important for both normal and disease-altered mechanisms of vascular function. While the conclusions in the paper are supported by the data, the data are exclusively transcriptome analysis, limiting the potential mechanistic and biological insights into questions such as what signals from macrophages or platelets stimulate the transcriptome-wide effects; how Rbfox2 coordinates, through changes in activity or concentration, the low flow-induced changes in endothelial cells; or what physiologic impact the Rbfox2 knockout has on the response to low flow conditions. Addressing such questions would greatly broaden the interest of the paper.

Essential revisions:

1\) Do the Rbfox2 ECKOs have any noticeable phenotype? For instance, do these mice exhibit an altered response to low flow when compared to littermate controls? Transcriptome-wide changes are presented but are not investigated further. The only physiologic data presented for Rbfox2 ECKOs is expression of macrophage markers. If the mutant phenotype has already been examined in more detail without finding a major difference from wildtype, this should be discussed.

2\) As is alluded by the authors in the Discussion, the immune response to low flow occurs rapidly. However, the disease progression involves a chronic inflammatory response. The authors should check if the initial transcriptome changes persist in the wildtype, immune response depleted, and Rbfox2 EC-KOs over a longer time period. Another round of RNA-seq is not necessary, but additional verification by qPCR and splice assays of key events will be a valuable addition.

3\) It is unclear how Rbfox2 activity responds to low flow since the authors state that Rbfox2 mRNA expression changes modestly under these conditions. Have they confirmed this at the protein level? Moreover, Rbfox proteins have both nuclear and cytoplasmic isoforms, with the cytoplasmic forms regulating transcript levels through 3\' UTR binding. The authors should assess how much Rbfox2 is in the cytoplasm of endothelial cells and whether this cytoplasmic Rbfox2 is causing some of the changes in gene expression observed in low flow conditions. This would yield a more complete picture of the post-transcriptional endothelial regulatory program induced by low flow.

10.7554/eLife.29494.044

Author response

> Essential revisions:
>
> 1\) Do the Rbfox2 ECKOs have any noticeable phenotype? For instance, do these mice exhibit an altered response to low flow when compared to littermate controls? Transcriptome-wide changes are presented but are not investigated further. The only physiologic data presented for Rbfox2 ECKOs is expression of macrophage markers. If the mutant phenotype has already been examined in more detail without finding a major difference from wildtype, this should be discussed.

We examined a number of responses in the Rbfox2-ECKO mice in the acute low flow model, including the transcriptional responses described in the paper. We have not observed obvious phenotypes in arterial hemorrhage, neointima growth, or differences in the recruitment of Cd68+ or F4/80+ macrophages or Cxcr2+ neutrophils, based on cell-specific RNA transcripts in the intima in this model. These findings are now described in the Discussion (subsection "Biological consequences of alternative splicing programs induced by low flow"). We predict, based on the intimal transcriptional changes observed ([Figure 5](#fig5){ref-type="fig"}), that adaptive responses could be affected. We have additional data to support this hypothesis; see [Author response image 1](#respfig1){ref-type="fig"}, which reveals that culture on Rbfox2-ECKO endothelial cells shows differential activation of a number of genes in monocytes as compared with culture on control endothelial cells (e.g. Tmem176a, Tmem176b, Gpx3, Hpgd). Tmem176b is also known as Torid (tolerance-related and induced), and along with Tmem176a is downregulated during dendritic cell differentiation in response to LPS, poly I:C, and overexpression of Tmem176b suppresses MHCII expression on LPS-treated bone marrow derived monocytes (PMID: 20501748, 16095493). We have not included these preliminary data in the revised manuscript since they require further extension, which requires modifications to the disturbed flow model to promote the adaptive response. This work is underway, but the establishment of these models and their characterization will take more time and is beyond the scope of this paper.

![Endothelial cells deficient in Rbfox2 alter the response of co-cultured monocytes and replicate aspects of the in vivo intimal response.\
Wild-type bone marrow monocytes were isolated and cultured for 5 days on Rbfox2-ECKO or control aortic endothelial cells (N=5 and N=7). Transcriptome of the initial monocytes and the co-cultured monocytes was analyzed by RNA-seq. (**A**) Overlap of the genes with pvalue\<0.05 by DESeq2 with the genes identified by the same threshold in vivo. (**B**) Comparison of the fold-change observed in vitro, in co-cultured monocytes, and in vivo, in the intimal flush of low-flow carotid arteries. In red/pink are genes concordant in both, in blue are genes with opposing changes in vivo and in vitro. (**C**) Log2 fold-change (relative to the input monocytes at Day0) in monocytes cultured on biological replicates of Rbfox2-ECO or WT aortic endothelial cells.](elife-29494-resp-fig1){#respfig1}

> 2\) As is alluded by the authors in the Discussion, the immune response to low flow occurs rapidly. However, the disease progression involves a chronic inflammatory response. The authors should check if the initial transcriptome changes persist in the wildtype, immune response depleted, and Rbfox2 EC-KOs over a longer time period. Another round of RNA-seq is not necessary, but additional verification by qPCR and splice assays of key events will be a valuable addition.

We agree with the reviewers that an examination of the effects of innate immune cell recruitment and Rbfox2 regulation on the chronic low-flow injury response is warranted. Following their suggestion, and our own interest, we have depleted platelets from the low flow artery two weeks after the induction of low flow, and found that this late depletion was insufficient to revert EIIIA splicing changes, or PAI1 expression, a marker of endothelial cell activation ([Author response image 2](#respfig2){ref-type="fig"}). However, this late-stage response is complex. In the absence of platelets, both PAI1 and EIIIA expression appeared elevated, suggesting a role at this stage which opposes the earlier acute functions of platelets. However, there are other components of this late response which also do not conform with the early response. Cd68, for example, is no longer elevated in the low flow artery. At this point, our understanding of immune-endothelial interactions during chronic disease progress is inadequate. More work will be required to determine why platelet depletion would exert different responses depending on the timing. Better, and more cost-effective models must be adapted to allow the chronic depletion of platelets in this response for several weeks, without the potential immune complications of long term antibody mediated depletion. As discussed above, ongoing work is focused on the establishment of these models, and an examination of the role of splicing changes in the chronic inflammatory response. The current paper does not directly address this, and will not be able to do so without new models and substantial additional work, so again we have not included these preliminary data in the revised manuscript.

![Late platelet depletion in chronic low flow injury is insufficient to reverse EIIIA splicing and PAI1 expression.\
Wild-type mice were subjected to partial carotid ligation, and two weeks later platelets were depleted or not. Six days after depletion, intimal RNA flushes were obtained, and levels of gene expression assessed by qPCR.](elife-29494-resp-fig2){#respfig2}

> 3\) It is unclear how Rbfox2 activity responds to low flow since the authors state that Rbfox2 mRNA expression changes modestly under these conditions. Have they confirmed this at the protein level? Moreover, Rbfox proteins have both nuclear and cytoplasmic isoforms, with the cytoplasmic forms regulating transcript levels through 3\' UTR binding. The authors should assess how much Rbfox2 is in the cytoplasm of endothelial cells and whether this cytoplasmic Rbfox2 is causing some of the changes in gene expression observed in low flow conditions. This would yield a more complete picture of the post-transcriptional endothelial regulatory program induced by low flow.

Given the challenges of staining of nuclear vs. cytoplasmic protein in the very thin endothelial cell layer in vivo, or specifically isolating protein from this layer, we have examined cellular localization of Rbfox2 in vitro, where splicing is regulated as in vivo by the addition of monocytes, platelets and plasma or by the serum derived from their combination. In endothelial cells in vitro, Rbfox2 protein appears primarily nuclear by immunofluorescence, with no discernable change upon treatment with serum. These data are now presented as [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, and described in the Results (subsection "Endothelial-specific deletion of Rbfox2 partially reverts flow-responsive skipping of vascular skipped exons induced by low flow in vivo", fourth paragraph) and Discussion (subsection "Endothelial functions of Rbfox2", second paragraph). However, an important caveat to these in vitro experiments with regard to transcript regulation in the cytoplasmic pool is that, while in vivo Rbfox2-mediated splicing changes are replicated in vivo, changes in transcript levels were not. Thus, the in vitro system may not be positioned to define the contribution of cytoplasmic Rbfox2. Unfortunately, as mentioned earlier, the in vivo system is not amenable to this analysis either. Nevertheless, arguing against a direct regulation of transcripts by cytoplasmic Rbfox2, we find no enrichment in Clip-Seq-defined Rbfox binding sites in the 3'UTR of transcripts whose levels (not splicing) were Rbfox2 regulated. These analyses are now described in the Results (subsection "Endothelial deletion of Rbfox2 alters the intimal response to low flow", second paragraph) and Discussion (subsection "Endothelial functions of Rbfox2", third paragraph).
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